Federal government: Mylan has been overcharging for EpiPens

Archives
11522429_G_1152242971

By The Associated Press

Even the federal government is apparently paying too much for EpiPens, along with angry patients and insurers.

The skyrocketing price of the life-saving allergy shot, which has triggered a storm of criticism, is only part of the problem. Now the federal government, responding to Congressional inquiries, says Medicaid has for years been paying too much for EpiPens because the emergency shot is classified incorrectly as a generic medicine.

The federal government says EpiPen is a branded drug, which means the drug’s maker, Mylan, should have been paying the government a far higher rebate under the government’s complex pricing rules. Mylan could face steep penalties.

Mylan, which has been blasted for hiking EpiPen’s price to $608 from $94 since 2007, denies wrongdoing.

Copyright 2016 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Copyright 2019 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

video

More Video

Direct TV

Job and Career Fair

Click to Enter

Ohio Lottery

Trending Stories

More Top News

WTRF 7News Twitter